Summary & Overview
HCPCS Level II J0691: Injection, lefamulin, 1 mg
HCPCS Level II code J0691 designates the injectable antibiotic lefamulin at a unit of 1 mg. As a drug-specific HCPCS Level II code, it is used on medical claims to report the administered amount of lefamulin for outpatient infusion, clinic-administered injections, emergency department care, or inpatient medication billing. Accurate reporting of J0691 is important for clinical documentation, inventory control, and payer adjudication across national payers.
Key payers included in coverage and benchmarking discussions are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of where J0691 is used clinically, common billing considerations, and the types of benchmarks and policy updates that typically affect drug-specific HCPCS codes. The publication summarizes typical sites of service, common modifier usage where applicable, and the role of the code in medical claims for injectable antibiotic therapy.
This resource is intended to inform coding, billing, and policy teams about the clinical context and claim-line relevance of J0691, highlight payer coverage landscape at a national level, and outline the categories of benchmarks and policy changes that stakeholders should monitor.
Billing Code Overview
HCPCS Level II code J0691 describes Injection, lefamulin, 1 mg. This code represents a single unit of the intravenous or intramuscular antibiotic lefamulin, packaged or dosed such that each billed unit equals 1 mg of the drug. The service type is drug administration via injection, and the typical site of service is outpatient infusion/clinic, emergency department, or inpatient hospital setting, depending on clinical need and route of administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient infusion center or hospital outpatient department with a bacterial community-acquired pneumonia or other indicated acute bacterial infection requiring intravenous or intramuscular administration of the pleuromutilin antibiotic lefamulin. The patient often has failed or is intolerant to first-line oral antibiotics, has significant comorbidities (for example chronic obstructive pulmonary disease or heart failure) that warrant parenteral therapy, or requires a single-dose parenteral course prior to transition to oral therapy. Clinical workflow: patient evaluation with history and physical, chest imaging and relevant labs, order for antimicrobial therapy specifying J0691 (lefamulin, per mg), pharmacy preparation and dose calculation using body weight and renal/hepatic considerations, administration by an appropriately credentialed clinician (RN or physician) in an ambulatory infusion center, observation for immediate adverse reactions, documentation of lot number and units administered, and discharge instructions with follow-up and transition to oral therapy when indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Default when no specific modifier applies to the service |